138
Participants
Start Date
December 10, 2018
Primary Completion Date
November 17, 2023
Study Completion Date
November 17, 2023
INCB086550
INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.
Chu Hopital de La Timone, Marseille
University of Pennsylvania Health System, Philadelphia
Jefferson University Hospitals, Philadelphia
Georgetown University Hospital, Washington D.C.
Irrcs Instituto Clinico Humanitas, Rozzano
Fondazione Irccs Istituto Nazionale Dei Tumori, Milan
European Institute of Oncology, Milan
Aamc Oncology and Hematology, Annapolis
Institut Universitaire Du Cancer de Toulouse Oncopole, Toulouse
H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa
Icm Montpellier, Montpellier
Sarah Cannon Research Institute, Nashville
Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte, Siena
Institut Curie, Paris
Md Anderson Cancer Center, Houston
Istituto Nazionale Tumori Irccs Fondazione Pascale, Napoli
Institut Jules Bordet, Brussels
Universitair Ziekenhuis Antwerpen (Uza), Edegem
Universitair Ziekenhuis Gent, Ghent
Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven
Addenbrooke'S Hospital, Cambridge
Guys and St Thomas Nhs Foundation Trust, London
Imperial College Healthcare Nhs Trust - Hammersmith Hospital, London
The Christie Nhs Foundation Trust Uk, Manchester
Weston Park Hospital, Sheffield
Lead Sponsor
Incyte Corporation
INDUSTRY